B
Beam Therapeutics
developing precision genetic medicines for serious diseases
At a glance
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later10 investors entered at this stage
Cormorant Asset Management- AVAltitude Life Science Ventures
F-Prime- HUHarvard University
- OFOmega Funds
- DRDreamers
- RGRedmile Group
- DHDHVC
ARCH Venture Partners
Eight Roads Ventures
Source: Dealroom Talent Intelligence.
Alumni founders
Former Beam Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
PAPairwiseEst. 2017
David LiuUnited States
PMPrime MedicineEst. 2019
VTVerve TherapeuticsEst. 2018
Keith JoungUnited States
OTOrbital TherapeuticsEst. 2022Global footprint
team presence
across markets
Patents
90 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beam Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beam Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
